BioCryst's First Profitable Year Recasts Hereditary Angioedema Growth Story [Yahoo! Finance]
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioCryst Pharmaceuticals (NasdaqGS:BCRX) reported its first full year of profitability, supported by commercial traction for ORLADEYO. The company acquired Astria Therapeutics, adding a late stage hereditary angioedema therapy and a pediatric FDA approved asset to its portfolio. These moves reshape BioCryst's hereditary angioedema franchise and mark a new phase for the business. BioCryst, trading at around $8.75, has seen its share price move 17.4% over the past week and 33.0% over the past month, with a 16.7% gain year to date. Over longer horizons, returns are more muted, with 1.6% over 1 year, essentially flat performance over 3 years, and a 21.5% decline across 5 years. This provides context for how significant this recent profitability milestone may appear to existing holders. For investors, the comb
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio [Yahoo! Finance]Yahoo! Finance
- BioCryst (BCRX) Soars 10.8% on Swing to Profits [Yahoo! Finance]Yahoo! Finance
- Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? [Yahoo! Finance]Yahoo! Finance
BCRX
Earnings
- 2/26/26 - Beat
BCRX
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- BCRX's page on the SEC website